4MK7

Hepatitis C Virus polymerase NS5B genotype 1b (BK) in complex with inhibitor 2 (3-(3-tert-butyl-4-methoxyphenyl)pyridin-2(1H)-one)

Summary for 4MK7

• Entry DOI: 10.2210/pdb4mk7/pdb
• Related: 4MIA 4MIB 4MK8 4MK9 4MKA 4MKB
• Descriptor: RNA-DIRECTED RNA POLYMERASE, MAGNESIUM ION, DIMETHYL SULFOXIDE, ... (5 entities in total)
• Functional Keywords: polymerase, transferase, ns5b, transferase-transferase inhibitor complex, transferase/transferase inhibitor
• Biological source: Hepatitis C virus (HCV)
• Cellular location: Core protein p21: Host endoplasmic reticulum membrane; Single-pass membrane protein. Core protein p19: Virion (By similarity). Envelope glycoprotein E1: Virion membrane; Single-pass type I membrane protein (Potential). Envelope glycoprotein E2: Virion membrane; Single-pass type I membrane protein (Potential). p7: Host endoplasmic reticulum membrane; Multi-pass membrane protein (By similarity). Protease NS2-3: Host endoplasmic reticulum membrane; Multi-pass membrane protein (Potential). Serine protease NS3: Host endoplasmic reticulum membrane; Peripheral membrane protein (By similarity). Non-structural protein 4A: Host endoplasmic reticulum membrane; Single-pass type I membrane protein (Potential). Non-structural protein 4B: Host endoplasmic reticulum membrane; Multi-pass membrane protein (By similarity). Non-structural protein 5A: Host endoplasmic reticulum membrane; Peripheral membrane protein (By similarity). RNA-directed RNA polymerase: Host endoplasmic reticulum membrane; Single-pass type I membrane protein (Potential): P26663
• Total number of polymer chains: 2
• Total formula weight: 127404.66

Authors

Harris, S.F.,Wong, A. (deposition date: 2013-09-04, release date: 2013-10-09, Last modification date: 2024-02-28)

Primary citation

Schoenfeld, R.C.,Bourdet, D.L.,Brameld, K.A.,Chin, E.,de Vicente, J.,Fung, A.,Harris, S.F.,Lee, E.K.,Le Pogam, S.,Leveque, V.,Li, J.,Lui, A.S.,Najera, I.,Rajyaguru, S.,Sangi, M.,Steiner, S.,Talamas, F.X.,Taygerly, J.P.,Zhao, J.
Discovery of a Novel Series of Potent Non-Nucleoside Inhibitors of Hepatitis C Virus NS5B.
J.Med.Chem., 56:8163-8182, 2013

PubMed Abstract: Hepatitis C virus (HCV) is a major global public health problem. While the current standard of care, a direct-acting antiviral (DAA) protease inhibitor taken in combination with pegylated interferon and ribavirin, represents a major advancement in recent years, an unmet medical need still exists for treatment modalities that improve upon both efficacy and tolerability. Toward those ends, much effort has continued to focus on the discovery of new DAAs, with the ultimate goal to provide interferon-free combinations. The RNA-dependent RNA polymerase enzyme NS5B represents one such DAA therapeutic target for inhibition that has attracted much interest over the past decade. Herein, we report the discovery and optimization of a novel series of inhibitors of HCV NS5B, through the use of structure-based design applied to a fragment-derived starting point. Issues of potency, pharmacokinetics, and early safety were addressed in order to provide a clinical candidate in fluoropyridone 19.

PubMed: 24069953
DOI: 10.1021/jm401266k

Experimental method

X-RAY DIFFRACTION (2.8 Å)